ALNY - Alnylam soars 48% as Phase 3 trial for ATTR amyloidosis therapy meet main goal

• Alnylam Pharmaceuticals ( NASDAQ: ALNY ) added ~48% in the pre-market Wednesday after the RNAi therapeutics company said that its Phase 3 trial for patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy reached the main goal.
• The APOLLO-B trial involving 300 adult patients globally reached the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo with statistical significance (p-value 0.0162), according to Alnylam ( ALNY ).
• In addition, the drug known as Onpattro also reached the first secondary endpoint: the change in quality of life compared to placebo from baseline in terms of Kansas City Cardiomyopathy Questionnaire (KCCQ) (p-value 0.0397).
• The company intends to submit a Supplemental New Drug Application to the FDA in late 2022 and present APOLLO-B data at a medical conference in Heidelberg, Germany.

For further details see: